IL1F10 and prostate carcinoma: Multivariate analysis further revealed that IL-38 expression (HR 6.73; 95%1.36-33.19; p=0.019) and TNM staging (HR 14.03; 95%1.67-118.23; p=0.015) were independent and reliable biomarkers predicting the survival rates of these prostate cancer patients.